First participant dosed in a Phase 1 clinical evaluation of a fusion protein vaccine designed to provide ‘serotype-independent’ protection against disease caused by multiple Streptococcus pneumoniae serotypesBOSTON (BUSINESS WIRE) Vaccine development company Matrivax announces the start of its Phase 1 clinical stu.
/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.
/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.